Heparin-like effect in postcardiotomy extracorporeal membrane oxygenation patients by Marco Ranucci et al.
Ranucci et al. Critical Care 2014, 18:504
http://ccforum.com/content/18/5/504RESEARCH Open AccessHeparin-like effect in postcardiotomy
extracorporeal membrane oxygenation patients
Marco Ranucci*, Ekaterina Baryshnikova, Giuseppe Isgrò, Concetta Carlucci, Mauro Cotza, Giovanni Carboni
and Andrea BallottaAbstract
Introduction: Unfractionated heparin (UFH) is the anticoagulant of choice for extracorporeal membrane
oxygenation (ECMO), but bivalirudin can be used as an alternative. The purpose of the present study is to
investigate the existence of a heparin-like effect (HLE) during heparin-free ECMO.
Methods: This is a retrospective study on patients treated with ECMO and receiving bivalirudin as the sole
anticoagulant. Thromboelastography (TEG) tests with and without heparinase were recorded during the ECMO
duration. A total of 41 patients (22 pediatrics and 19 adults) treated with ECMO after cardiac surgery procedures
and receiving only bivalirudin-based anticoagulation were studied. Based on the presence of a different reaction
time (R-time) between the TEG test with heparinase or without heparinase we defined the presence of a HLE.
Survival to hospital discharge, liver failure, sepsis, bleeding and transfusion rate were analyzed for association with
HLE with univariate tests.
Results: HLE was detected in 56.1% of the patients. R-times were significantly shorter in tests done with heparinase
versus without heparinase during the first seven days on ECMO. Patients with HLE had a significantly (P = 0.046)
higher rate of sepsis (30%) than patients without HLE (5.6%) at a Pearson’s chi-square test.
Conclusions: A heparin-like effect is common during ECMO, and most likely due to a release of heparinoids from
the glycocalyx and the mast cells, as a consequence of sepsis or of the systemic inflammatory reaction triggered
by the contact of blood with foreign surfaces.Introduction
Patients under extracorporeal membrane oxygenation
(ECMO) require anticoagulation to prevent circuit and
intravascular thrombosis. The usual anticoagulant is intra-
venous unfractionated heparin (UFH), at variable doses
ranging from 20 IU/kg/h to 70 IU/kg/h [1]; however,
alternative anticoagulants like bivalirudin have been
proposed in patients with [2,3] or without heparin-induced
thrombocytopenia [4-6].
At our institution, bivalirudin is the first choice for
post-cardiotomy veno-arterial or veno-venous ECMO
both in adult and pediatric patients, unless there is evi-
dence of blood stagnation inside the cardiac chambers
[5,6]. The assessment of the adequacy of anticoagulation
includes serial measurements of the activated clotting* Correspondence: cardioanestesia@virgilio.it
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unless otherwise stated.time (ACT), activated partial thromboplastin time (aPTT),
and thromboelastography (TEG).
By running TEG examination with and without hepari-
nase, we started noticing different patterns of TEG profiles
in some patients. One typical pattern observed in these
cases is represented in Figure 1, and is characterized by a
remarkably shorter reaction time (R-time) when the test is
carried out with kaolin activation plus heparinase with
respect to kaolin activation alone. This is suggestive for
a heparin-like effect (HLE), in absence of any UFH
treatment.
The present study is a retrospective review of a series
of patients treated with heparin-free ECMO. The aim of
the study is to confirm our hypothesis that ECMO
patients may experience a heparin-like effect during the
course of the ECMO treatment.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 An example of heparin-like effect on thromboelastography (kaolin activation). Black tracing, test without heparinase; green tracing,
test with heparinase. ECMO, extracorporeal membrane oxygenation.
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Patients undergoing ECMO treatment at our institution
are routinely included in an ECMO registry. The first
patient treated with bivalirudin as the sole anticoagulant
was reported in March 2010. From March 2010 to
February 2014, 68 ECMO procedures were recorded.
Twenty-seven patients were treated with UFH on ECMO.
Forty-one patients were treated with bivalirudin as the
sole anticoagulant during ECMO. For these patients, we
have retrieved the TEG data measured during the ECMO
period, which is stored in the memory file of the TEG
device, the values of aPTT and international normalized
ratio (INR), and transfusion data (packed red cells, fresh
frozen plasma, and platelet concentrates).
The present study was approved by the local ethics
committee (San Raffaele Hospital ethics committee), and
the need for informed consent from the patients was
waived, given the retrospective nature of the study and
the existence of all data in a dedicated registry. At
hospital admission, all patients gave written approval
for the treatment of their data in an anonymous form
for scientific purposes.
Patient population
Forty-one patients suitable for the present analysis were
identified. Patients who received heparin after the
ECMO placement were excluded from the analysis. A
control group of 12 patients not on ECMO was included;
these patients were receiving TEG analysis for diagnosis of
bleeding on the first day after cardiac surgery.
ECMO procedure
The following ECMO circuits have been used during the
study period: for patients below 10 kg body weight the cir-
cuit was assembled using a centrifugal pump BiomedicusBP50 (Medtronic, Minneapolis, MN, USA) and an oxygen-
ator Dideco Lilliput 2 ECMO (Sorin Group, Mirandola,
Italy) with phosphorylcholine-biocompatible treatment. For
patients weighing >10 kg different circuits have been used
according to availability: the centrifugal pumps used were
the Biomedicus BP 80 (Medtronic), the Stockert Revolu-
tion (Sorin Group), the Levitronix (Waltham, MA, USA)
equipped with the Dideco EOS ECMO (Sorin Group) oxy-
genator with phosphorylcholine-biocompatible treatment
(Phisio, Sorin Group). Starting in 2012, a pre-assembled
ECMO system (Permanent Life Support, Maquet, Rastatt,
Germany) with a Rotaflow centrifugal pump, and a Quadrox
PLS oxygenator with Bioline® coating was used in adult
patients. The ECMO was usually performed at full flow,
under normothermic conditions guaranteed by the oxy-
genator heat exchanger, a heater-cooler external group,
and external heat-exchanging blankets.
Anticoagulation protocol and transfusion policy
Anticoagulation monitoring during ECMO was obtained
using the ACT, the aPTT, and kaolin-activated throm-
boelastography (TEG, Haemoscope, Niles, IL, USA). The
ACT was initially repeated every 4 h and the target value
was 160 to 180 seconds. Subsequently, it was progressively
replaced by the TEG, repeated every 8 h, with a target
value for the R-time placed at a minimum of 12 and a
maximum of 30 minutes. The aPTT was repeated every
12 h, with a target value of 50 to 80 seconds.
The initial anticoagulation protocol was different de-
pending on the timing of the ECMO implant. In patients
under cardiopulmonary bypass with full heparin treat-
ment, where the ECMO was implanted due to the inability
to wean the patient from the cardiopulmonary bypass, the
heparin was fully antagonized with protamine after the
ECMO implantation, and the effectiveness of heparin
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patient was observed for bleeding control. In the case of
active bleeding (>4 mL/kg/h) no anticoagulants were
used. Once the blood loss was contained and stabilized,
the anticoagulation protocol was started and modulated
to stick to the optimal coagulation values previously
described.
In patients where the systemic heparin used for the
cardiac operation was already antagonized, and the ECMO
was implanted subsequently to protamine administration, a
bolus dose of heparin (100 IU/kg) was used for cannulation.
Once the ECMO was established, the heparin was fully
antagonized with protamine and again the patient entered
the observation period for severe bleeding before starting
any anticoagulation treatment.
Once major bleeding was ruled out, all patients started
anticoagulation with a continuous infusion of bivalirudin
at an initial dose of 0.05 μg/kg/h. The dose was subse-
quently adjusted according to the ACT, aPTT, and R-time
values. In patients with reduced creatinine clearance, the
starting dose was halved. Details of the bivalirudin-
based anticoagulation protocol have been previously
reported [6].
Data collection and definitions
For each patient we retrieved the demographic data, the
nature of the ECMO treatment (veno-venous or veno-
arterial), the use of phosphorylcholine or heparin coating
of the circuit and oxygenator; and some outcome indica-
tors including peak serum bilirubin value during ECMO,
sepsis (signs of systemic inflammatory reaction and posi-
tive blood cultures), bleeding (mL/kg/day), and survival
to hospital discharge. Additionally, we retrieved all the
TEG tracings collected during the ECMO period. We
recorded the R-time of kaolin-activated whole blood
with or without heparinase. For every day on ECMO, we
recorded the R-times having the larger difference between
TEG tracings with or without heparinase. Therefore, we
obtained the daily values of R-times more representative
of the phenomenon we wanted to explore. The obser-
vation period was extended to no more than 12 days on
ECMO. For the purposes of the present study, we defined
an HLE as the presence of at least one TEG analysis show-
ing an R-time of the test with heparinase at least 30%
shorter than the correspondent R-time of the test without
heparinase.
Statistics
Normality of continuous data distribution was checked
with a Kolgomorov-Smirnov test. Differences between
R-times with or without heparinase were tested with the
paired data Student’s t-test. Time-related differences
were investigated with analysis of variance for repeated
measures. Associations between HLE and other parameterswere explored using Pearson’s chi-square test, Student’s
t-test, or non-parametric tests when appropriate. A
P-value <0.05 was considered significant for all the tests
applied. For all the statistical analyses a computerized
package (IBM SPSS 20.0, Chicago, IL, USA) was used.
Results
The characteristics of the patient population are shown
in Table 1. The 22 pediatric patients included 7 newborn
babies (weight 3.2 ± 0.6 kg, range 2.3 to 4.0 kg), 9 infants
age ≤1 year weight 6.0 ± 1.2 kg, range 4.6 to 7.6 kg) and
6 patients age >1 year (weight 26.1 ± 15.0 kg, range 13 to
45 kg). They were submitted to different corrective or
palliative procedures, including six arterial switch opera-
tions for transposition of the great vessels, six valvular
repair/replacements, two systemic-to-pulmonary shunts,
one complete atrioventricular canal, one Rastelli oper-
ation, one total anomalous pulmonary venous return,
one Norwood operation and four complex, combined
procedures.
There were 23 (56.1%) patients fulfilling the criteria
for HLE. We could not identify any factor related to age
and ECMO characteristics showing an association with
HLE. Patients who demonstrated an HLE had a signifi-
cantly (P = 0.008) longer duration of ECMO. There was
no association between HLE, bleeding, and peak serum
bilirubin values. Conversely, there was a significantly
(P = 0.046) higher rate of patients with sepsis in the
HLE group.
The patterns of the R-times with and without hepa-
rinase are shown in Figure 2. At any point in time,
the R-time of the TEG with heparinase was shorter
than the correspondent R-time of the TEG without hepa-
rinase. This difference was statistically significant on day 1
through day 7 (with P-values ranging from 0.004 to 0.047)
and on day 9 (P = 0.012). On day 8, and from day 10
through day 12, no significant difference was observed.
The overall effect of time was not significantly associated
with the changes in R-time at the TEG with (P = 0.909) or
without (P = 0.652) heparinase.
The first TEG done immediately after positioning of
the ECMO and protamine antagonization of heparin dem-
onstrated a small, non-significant difference in R-times,
with an R-time of 10.7 ± 4.5 minutes for TEG without
heparinise and 9.6 ± 4.0 minutes for TEG with heparinase.
In the control group of patients analyzed with TEG with
or without heparinase, there was no significant difference
in the R-time 24 h after surgery.
The patterns of aPTT and INR during ECMO are
reported in Figures 3 and 4, respectively. The aPTT was
longer in the HLE patients during the first 5 days on
ECMO, although not significantly. On day 9 the differ-
ence became significant (P = 0.023). No differences were
observed with respect to the INR.
Table 1 Characteristics of the patient population, of the ECMO, and outcome data
Variable Overall (n = 41) HLE (n = 23) No HLE (n = 18) P-value
Pediatric patients (<16 years), number (%) 22 (53.7) 12 (52.2) 10 (55.6) 0.829
Veno-venous ECMO, number (%) 8 (19.5) 5 (21.7) 3 (16.7) 0.684
Veno-arterial ECMO, number (%) 33 (80.5) 18 (78.3) 15 (83.3)
Phosphorylcholine coating, number (%) 29 (70.7) 15 (65.2) 14 (77.8) 0.380
Heparin coating, number (%) 12 (29.3) 9 (34.8) 4 (22.2)
Days on ECMO, median (range) 6 (1 to 12) 7 (3 to 12) 4 (1 to 12) 0.008
Bleeding on ECMO (mL/kg/day), mean (SD) 17 (13) 15.5 (14) 20.6 (11) 0.144
Peak serum bilirubin on ECMO, mg/dL, mean (SD) 4.4 (5.7) 3.7 (3.2) 5.3 (7.6) 0.410
Sepsis, number (%) 8 (19.5) 7 (30.4) 1 (5.6) 0.046
Survived to hospital discharge, number (%) 19 (46.3) 9 (39.1) 10 (55.6) 0.295
ECMO, extracorporeal membrane oxygenation; HLE, heparin-like effect.
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observe significant differences between patients with or
without HLE in the general patient population or in the
subgroups of pediatric and adult patients.
Discussion
Our study demonstrates that despite the total absence of
UFH during the ECMO period, ECMO patients may
exhibit different R-times at the TEG performed with or
without heparinase, therefore simulating the presence of
circulating heparin. This effect becomes progressively
more evident from the ECMO initiation through the
fifth day on ECMO, subsequently declining and disap-
pearing after 10 days on ECMO. We could not identify
any predictor of the HLE, and the longer ECMO dur-
ation observed in patients with HLE is probably simply
the expression that the longer the period of observa-
tion, the higher is the probability to detect the HLE.
It is important to note that HLE has a higher incidenceFigure 2 Reaction times (R-time) on thromboelastography (TEG)
with and without heparinase during the first 12 days on
extracorporeal membrane oxygenation (ECMO). Data refer to the
whole patient population and are mean values of the different tests
done on the same day. *P <0.05; **P <0.01.in patients who developed sepsis during the ECMO
treatment.
There are different possible explanations for the HLE
phenomenon during ECMO. A first possibility is that
the difference in R-times with or without heparinase
may be ascribed to the well-known inter-examination
variations of the TEG technology. TEG has a relatively
high coefficient of variation [7]; however, this is usually
no greater than 10%. In our series, the mean difference
between R-times with or without heparinase exceeded
30% in the first 6 days on ECMO and was almost 100%
on day 4 and 5 on ECMO. Therefore, the difference that
we observed was largely greater than could be expected
for the inter-examination TEG coefficient of variation,
and cannot be attributed to this effect.
The most common cause of differences in R-times with
or without heparinase is the presence of residual circulat-
ing heparin that is not completely antagonized by protam-
ine. In our series, full protaminization was achieved once
the ECMO was established, and immediately after ECMOFigure 3 Acivated partial thromboplastin time (aPTT) in the
heparin-like effect (HLE) versus no-HLE groups during the first
12 days on extracorporeal membrane oxygenation (ECMO).
*P <0.05.
Figure 4 International normalized ratio (INR) in the heparin-like
effect (HLE) versus no-HLE groups during the first 12 days on
extracorporeal membrane oxygenation (ECMO).
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differences in R-times with or without heparinase. It
is therefore unlikely after many days from the last dose of
intraoperative heparin that residual effects of this drug will
be noticed. However, to rule out this possibility, we have
retrospectively analyzed a control group of 12 patients
scrutinized with TEG on the first day after surgery due to
ongoing microvascular bleeding. Our results clearly dem-
onstrated that no significant differences in R-times were
detectable only 24 h after surgery.
A third interpretation can be applied to the cases
where a heparin-coated circuit was used. It cannot beTable 2 Transfusional needs during ECMO in the patient pop
Total patient population (n = 41) HLE
Blood product
Number of patients 23
Packed red cells, mL/kg/day, mean (SD) 25 (2
Fresh frozen plasm, mL/kg/day, mean (SD) 8.9 (1
Platelet concentrate, mL/kg/day, mean (SD) 3.5 (5
Adult patients (n = 19)
Blood product
Number of patients 11
Packed red cells, mL/kg/day, mean (SD) 8.6 (5
Fresh frozen plasma, mL/kg/day, mean (SD) 2.2 (2
Platelet concentrates, mL/kg/day, mean (SD)) 1.7 (1
Pediatric patients (n = 22)
Blood product
Number of patients 12
Packed red cells, mL/kg/day, mean (SD) 38.7 (
Fresh frozen plasma, mL/kg/day, mean (SD) 14.4 (
Platelet concentrates, mL/kg/day, mean (SD) 5.1 (7
ECMO: extracorporeal membrane oxygenation; HLE: heparin-like effect.excluded that variable doses of heparin may leave the
surface of the circuit/oxygenator and enter the systemic
circulation while on ECMO. However, we observed the
phenomenon in patients treated with phosphorylcholine
coatings as well as in patients treated with heparin coat-
ings, and we therefore exclude this interpretation.
Our interpretation is that ECMO patients experience
an HLE as observed in other clinical conditions character-
ized by endothelial disturbance. The endothelial glycocalyx
contains the glycosaminoglycans (GAGs) heparan sulfate,
chondroitin sulfate and hyaluronan [8]. These substances
act like heparinoids, and are scavenged by heparinase [8].
Their release into the systemic circulation determines
effects that are similar to those obtained by exogenous
UFH. Additionally, GAGs are produced by the mast cells
during sepsis or systemic inflammatory reaction syndrome
(SIRS) [9].
HLE has been previously demonstrated in three clin-
ical settings: acute liver failure during liver disease and
liver transplantation [10,11], sepsis/SIRS [12], and cancer
[13]. The mechanisms leading to the HLE are multifactor-
ial, and include (i) failure of the liver to clear the circulating
GAGs during acute liver failure [14], (ii) neutrophil-
mediated injury of the hepatocytes that can release hep-
arin sulphate [15], and (iii) the direct release of GAGs
from the endothelial surface and the mast cells during
sepsis/SIRS [15].
The occurrence of an HLE during ECMO may have a
multifactorial genesis. During ECMO, the chronic contact
of blood with foreign surfaces triggers contact-phaseulation
No HLE P-value
18
8) 27 (18) 0.783
4) 11.8 (16) 0.560
.7) 3.9 (4.1) 0.810
8
.6) 12.2 (2.8) 0.134
.7) 1.5 (1.9) 0.541
.6) 2.3 (2.7) 0.572
10
32) 38.6 (16) 0.995
18) 19.9 (18) 0.494
.3) 5.2 (4.8) 0.979
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flammatory system, leading to SIRS. The increased release
of cytokines during the SIRS determines an endothelial
injury. Additionally, due to the presence of a large number
of cannulas and venous catheters, ECMO patients are par-
ticularly susceptible to bloodstream infections and sepsis.
Sepsis is per se a determinant of cytokine release and dir-
ect release of heparinoids from the mast cells [15]. Finally,
it cannot be excluded that poor liver perfusion during
ECMO may trigger patterns of subacute liver failure.
However, in our series we did not detect any association
between the peak bilirubin value during ECMO and the
peak delta R-time with or without heparinase, and we
therefore tend to exclude this last mechanism.
As a matter of fact, in our series the HLE is not asso-
ciated with a significantly worse outcome in terms of
survival (39% in patients with HLE versus 55% in patients
without HLE); however, we must admit that this could
simply be due to the relatively limited sample size. Actu-
ally, the significantly higher rate of septic patients in the
HLE group suggests that HLE could be the expression
of a potentially severe clinical condition. In about 30%
of the patients with HLE, sepsis was probably the lead-
ing cause; in the remaining 70%, HLE is likely to be the
expression of a natural inflammatory reaction to the
blood exposure to foreign surfaces rather than a marker
of severe complications.
HLE in ECMO patients has never been reported
before. The main reason for this is that the great major-
ity of ECMO patients undergo anticoagulation with
UFH. Therefore, no possibility exists to separate the ef-
fects of endogenous heparinoids and exogeneous UFH.
Our model based on bivalirudin as the sole anticoagulant
provided us with the possibility to observe and measure
this phenomenon.
There are some limitations in our study. The retro-
spective nature could determine a risk of bias and of
exclusion of variables that may be associated with the
HLE phenomenon. Additionally, the relatively low num-
ber of patients does not allow multivariable analyses. We
must consider the heterogeneity of our patient popula-
tion, composed of newborn babies, infants, children, and
adult patients. Although age was not associated with a
different incidence of HLE, we cannot exclude that the
well-known differences in the coagulation pattern observed
in newborn babies and infants versus adult patients may
play a role in the determinism and severity of the HLE.
This is a single-center study, and our results need to be
confirmed in larger series of patients, and in patients in
whom the ECMO was applied in a non-postcardiotomy
setting. Additionally, other techniques for diagnosing an
HLE during ECMO (that is, direct measurement of hep-
arin concentration in bivalirudin-treated patients) could
confirm our findings.Conclusions
The potential therapeutic implications of our findings
are still to be defined. We cannot exclude that HLE in
patients undergoing anticoagulation with UFH on ECMO
may determine, contrary to our study based on bivalirudin
anticoagulation, an increased risk of bleeding, especially in
the early days on ECMO. Potential interventions include a
decrease of the UFH infusion dose, whereas the use of
protamine should probably be limited to patients with
severe, life-threatening bleeding. Protamine has been
successfully used for reversing HLE during liver trans-
plantation [16,17], but of course its use may trigger
thromboembolic events in the ECMO setting. In our
series, HLE was more common in patients with septic
conditions. In this respect, additional studies are certainly
needed to confirm HLE as a potential marker of systemic
infection.
In conclusion, we think that physicians managing
ECMO patients should be aware that a HLE may be
frequently found, especially in the first week of ECMO.
Detection of the HLE could trigger adequate interventions
in terms of UFH dose changes.Key messages
 During ECMO without heparinization,
the patients experience an HLE in about
50% of cases
 The HLE is evident during the first week on ECMO,
and decreases with time after the seventh day on
ECMO
 The HLE is not due to liver failure or heparin
coating of the ECMO system
 There is an association between the HLE and the
onset of sepsis, with a sepsis rate during ECMO of
30% in patients with an HLE, and of 6% in those
without this phenomenon.
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